Physician profile
Eric Paul Haus
NPI 1114128311
$15,955.05
in general payments reported to CMS, 2019-2025
59 companies · $3,063 in 2025
The $3,063 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,978 · 2020: $1,634 · 2021: $1,602 · 2022: $2,264 · 2023: $2,438 · 2024: $2,976 · 2025: $3,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,476.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,370.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,893.86 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,516.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,272.25 | 2019-2025 | |
| Glaxosmithkline, LLC. | $962.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $830.89 | 2019-2025 | |
| Lilly USA, LLC | $815.10 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $806.08 | 2019-2025 | Repatha, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $365.04 | 2019-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $340.43 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.89 | 2019-2025 | Jardiance |
| Allergan, INC. | $313.48 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $275.07 | 2022 | |
| Phathom Pharmaceuticals, INC. | $272.25 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $267.18 | 2021-2025 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $257.05 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $238.83 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Biohaven Pharmaceuticals, INC. | $188.60 | 2021 | |
| Exact Sciences Corporation | $180.69 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amarin Pharma, INC. | $173.24 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $155.88 | 2019-2024 | Zoryve, Livalo, Seglentis |
| Takeda Pharmaceuticals U.S.A., INC. | $151.18 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $141.44 | 2022-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $128.38 | 2022-2025 | Veozah, Myrbetriq |
| Mannkind Corporation | $115.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $113.86 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $107.73 | 2019-2021 | |
| Medtronic, INC. | $107.03 | 2025 | Corevalve Evolut R |
| Axsome Therapeutics, INC. | $85.95 | 2024-2025 | Auvelity |
| Mylan Specialty L.P. | $83.00 | 2021-2024 | Yupelri |
| Bausch Health US, LLC | $77.55 | 2020-2022 | |
| Dexcom, INC. | $74.75 | 2021-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $69.46 | 2021-2025 | Nexletol |
| Vanda Pharmaceuticals INC. | $63.12 | 2025 | Fanapt |
| Corcept Therapeutics | $60.41 | 2024-2025 | Korlym |
| Eisai INC. | $59.28 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $58.86 | 2019-2020 | |
| Edwards Lifesciences Corporation | $54.03 | 2022 | |
| Horizon Therapeutics Plc | $50.35 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $50.17 | 2023-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $47.41 | 2021-2023 | Camzyos |
| Paratek Pharmaceuticals, INC. | $42.90 | 2022-2023 | Nuzyra |
| Abbott Laboratories | $41.19 | 2019 | |
| Ironwood Pharmaceuticals, INC | $39.07 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $36.12 | 2024-2025 | Zenpep |
| Verona Pharma, INC. | $34.29 | 2025 | Ohtuvayre |
| Ethicon US, LLC | $30.69 | 2020 | |
| Lundbeck LLC | $30.13 | 2024-2025 | Rexulti |
| Currax Pharmaceuticals LLC | $26.39 | 2021-2023 | Contrave, Onzetra Xsail |
| Inspire Medical Systems, INC. | $24.60 | 2024 | Inspire |
| Genzyme Corporation | $23.47 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.48 | 2020 | |
| Pulmonx Corporation | $16.66 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Shire North American Group INC | $15.42 | 2019 | |
| Covis Pharma Gmbh | $14.21 | 2022 | |
| Genentech USA, INC. | $13.14 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.88 | 2021 | |
| Lucid Diagnostics INC. | $12.53 | 2022 | |
| Hikma Pharmaceuticals USA | $11.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Haus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.